A new trading day began on Tuesday, with Nuvation Bio Inc (NYSE: NUVB) stock price remained unchanged from the previous day of trading, before settling in for the closing price of $2.35. NUVB’s price has ranged from $1.54 to $3.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -49.14% over the last five years. Meanwhile, its annual earnings per share averaged 69.19%. With a float of $226.12 million, this company’s outstanding shares have now reached $338.84 million.
The firm has a total of 220 workers. Let’s measure their productivity. In terms of profitability, gross margin is 14.06%, operating margin of -5762.82%, and the pretax margin is -5534.21%.
Nuvation Bio Inc (NUVB) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nuvation Bio Inc is 33.54%, while institutional ownership is 48.29%. The most recent insider transaction that took place on Jun 18 ’25, was worth 17,100. In this transaction CHIEF PEOPLE OFFICER of this company bought 10,000 shares at a rate of $1.71, taking the stock ownership to the 29,591 shares. Before that another transaction happened on Jun 17 ’25, when Company’s Chief Financial Officer bought 4,000 for $1.79, making the entire transaction worth $7,160. This insider now owns 9,902 shares in total.
Nuvation Bio Inc (NUVB) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.04% during the next five years compared to -49.14% drop over the previous five years of trading.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Here are Nuvation Bio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 72.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.34, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Analysing the last 5-days average volume posted by the [Nuvation Bio Inc, NUVB], we can find that recorded value of 4.1 million was lower than the volume posted last year of 4.19 million. As of the previous 9 days, the stock’s Stochastic %D was 68.46%.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 68.64%, which indicates a significant decrease from 77.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.15 in the past 14 days, which was lower than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.16, while its 200-day Moving Average is $2.31. Now, the first resistance to watch is $2.40. This is followed by the second major resistance level at $2.45. The third major resistance level sits at $2.49. If the price goes on to break the first support level at $2.31, it is likely to go to the next support level at $2.27. Should the price break the second support level, the third support level stands at $2.22.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
With a market capitalization of 799.62 million, the company has a total of 340,263K Shares Outstanding. Currently, annual sales are 7,870 K while annual income is -567,940 K. The company’s previous quarter sales were 3,080 K while its latest quarter income was -53,240 K.
